Pancreatic Cancer Resectable Clinical Trial
Official title:
Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Pancreatic Cancer Using Ex Vivo Analysis of Organoid Culture
The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06375928 -
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)
|
N/A | |
| Recruiting |
NCT06388967 -
Pancreatic Cancer Detection Consortium
|
||
| Completed |
NCT05483257 -
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
|
||
| Recruiting |
NCT05287165 -
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
|
Early Phase 1 | |
| Not yet recruiting |
NCT06287749 -
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
|
||
| Recruiting |
NCT03977233 -
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT04224402 -
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
|
Phase 2 | |
| Terminated |
NCT03344172 -
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05479708 -
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
|
||
| Not yet recruiting |
NCT06368063 -
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
|
Phase 4 | |
| Not yet recruiting |
NCT05637567 -
Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
|
Phase 2 | |
| Recruiting |
NCT05181605 -
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
|
Phase 2/Phase 3 |